## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report a computational pipeline (pharmacophore modeling, virtual screening, molecular docking, and 200 ns molecular dynamics simulations) applied to identify five natural compounds (Z56811101, Z653426226, Z1097341967, Z92743432, Z464101066) as potential inhibitors of five NF-kappaB family proteins (c-Rel, RelA/p65, RelB, NF-kappaB1/p50, NF-kappaB2/p52) for breast cancer therapeutics. Binding affinities ranged from -6.8 to -8.0 kcal/mol, and all compounds were reported to show favorable drug-like properties.
- **Visible evidence base** Abstract text only; no methodological details, docking scores, simulation convergence data, pharmacophore validation, or compound structures provided
- **Missing materials affecting confidence** Full methods, docking pose figures, MD simulation trajectories and analyses (RMSD, RMSF, binding free energy calculations), pharmacophore model validation, ADMET data, compound structures, and any comparison with known inhibitors or experimental controls

## Reviewer
- **Overall assessment** The abstract presents a standard structure-based virtual screening and MD simulation study. The computational workflow is conventional, and the reported results are plausible but not novel in methodology. The key weakness is the lack of experimental validation, which the authors acknowledge. The claim that these compounds are "potential candidates" for breast cancer patients is overstated given the purely computational nature of the evidence and the absence of any cellular or in vivo data. The abstract does not provide sufficient detail to assess the technical rigor of the docking or simulation protocols.
- **Who would be interested in the results, and why** Computational chemists and structural biologists working on NF-kappaB inhibition or natural product-based drug discovery might find the identified compounds as starting points for further optimization. Researchers in breast cancer therapeutics with an interest in computational pre-screening could also find the approach relevant, though the lack of experimental follow-up limits broader appeal.
- **Major strengths** The study targets a clinically relevant protein family (NF-kappaB) with clear links to breast cancer. The use of multiple NF-kappaB family members is a reasonable breadth. The inclusion of 200 ns MD simulations is a positive step beyond simple docking. The authors explicitly acknowledge the need for experimental validation, which is honest.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
  - R1-M4
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
  - R1-m4
- **Technical failings that need to be addressed before the case is established** The absence of any experimental validation is the primary failing. Additionally, the abstract does not demonstrate that the docking scores are selective or superior to known NF-kappaB inhibitors, and the drug-like property claims are not substantiated with specific data.
- **Assessment against Nature-style criteria** 
  - Originality: Low. The combination of pharmacophore modeling, virtual screening, docking, and MD is routine and widely used. No novel methodological contribution is evident.
  - Scientific importance: Moderate. NF-kappaB is a validated target, but the findings are preliminary and do not advance mechanistic understanding or provide validated leads.
  - Interdisciplinary readership: Limited. The work is primarily of interest to computational biologists and medicinal chemists; the lack of experimental data reduces appeal to clinicians or cancer biologists.
  - Technical soundness: Not assessable from the abstract. Key parameters (e.g., docking scoring function, simulation force field, convergence criteria) are not reported.
  - Readability for nonspecialists: The abstract is accessible but uses jargon (e.g., "pharmacophore model") without sufficient explanation for a broad audience.
- **Recommendation posture** Currently not established from the provided evidence. The computational results are suggestive but require experimental validation and more detailed technical reporting before the claims can be supported.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that the five compounds are "potential candidate[s] for patients with breast cancer."
- **Evidence pointer** Abstract, final sentence
- **Concern** The claim of therapeutic potential is based solely on computational docking scores and MD simulations. No experimental data (e.g., cell viability assays, NF-kappaB reporter assays, or animal models) are presented to support biological activity or safety.
- **Why it matters** Computational predictions frequently fail to translate to in vitro or in vivo efficacy. Without experimental validation, the claim of patient relevance is unsupported and potentially misleading.
- **Resolution test** Provide experimental evidence, such as IC50 values in NF-kappaB-driven reporter cell lines or cytotoxicity assays in breast cancer cell lines, demonstrating target engagement and functional inhibition.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical rigor
- **Claim pointer** The authors report binding affinities of -6.8 to -8.0 kcal/mol and claim stability over 200 ns simulations.
- **Evidence pointer** Abstract, results section; location not provided
- **Concern** The abstract does not specify the docking method, scoring function, or the criteria used to assess MD stability. Binding free energies from docking are not reliable indicators of true affinity, and "stability" is not defined (e.g., RMSD thresholds, protein-ligand contact persistence).
- **Why it matters** Without methodological details, the technical soundness of the results cannot be evaluated. Docking scores alone are insufficient to establish binding, and MD stability claims require quantitative metrics.
- **Resolution test** Report the docking software and scoring function, provide RMSD and RMSF plots with defined stability criteria, and include binding free energy calculations (e.g., MM-PBSA or MM-GBSA) to support the affinity claims.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Target specificity
- **Claim pointer** The compounds are proposed as inhibitors of five NF-kappaB family proteins (c-Rel, RelA/p65, RelB, NF-kappaB1/p50, NF-kappaB2/p52).
- **Evidence pointer** Abstract, methods and results sections; location not provided
- **Concern** The abstract does not clarify whether each compound was tested against all five proteins or whether the reported affinities correspond to a single target. Selectivity among family members is not addressed, and off-target effects are not considered.
- **Why it matters** NF-kappaB family members have distinct and sometimes opposing functions. A compound that inhibits all five indiscriminately may have unpredictable biological consequences. Selectivity data are essential for assessing therapeutic potential.
- **Resolution test** Provide a matrix of docking scores and MD results for each compound against each of the five proteins, and discuss selectivity or lack thereof.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Comparative benchmarking
- **Claim pointer** The compounds are implied to be promising leads, but no comparison with known NF-kappaB inhibitors is provided.
- **Evidence pointer** Abstract, results section; location not provided
- **Concern** The abstract does not compare the identified compounds with existing NF-kappaB inhibitors (e.g., parthenolide, BAY 11-7082) in terms of binding affinity, drug-likeness, or predicted toxicity.
- **Why it matters** Without benchmarking, it is unclear whether these compounds offer any advantage over known inhibitors. The claim of "potential" is weakened by the absence of a comparative context.
- **Resolution test** Include docking and MD comparisons with at least one known NF-kappaB inhibitor under identical conditions, and discuss relative performance.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract, opening statistics
- **Evidence pointer** Abstract, first sentence
- **Issue** The epidemiological statistics ("every 19 s", "every 74 s") are presented without citation and may be outdated or context-dependent.
- **Required correction** Provide a recent, citable source for these statistics or remove them to avoid unsupported claims.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Terminology
- **Affected element** Abstract, "silent killer malady"
- **Evidence pointer** Abstract, first sentence
- **Issue** The phrase "silent killer malady" is informal and imprecise for a scientific abstract.
- **Required correction** Replace with a more standard phrase such as "a leading cause of cancer-related mortality among women."

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Compound identification
- **Affected element** Abstract, compound names
- **Evidence pointer** Abstract, results section
- **Issue** The compound identifiers (e.g., Z56811101) are not accompanied by chemical names, structures, or source information, making it impossible for readers to identify or reproduce the work.
- **Required correction** Provide chemical names, SMILES strings, or structures in the abstract or supplementary materials.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Drug-likeness claim
- **Affected element** Abstract, "maximum drug-like properties"
- **Evidence pointer** Abstract, final sentence
- **Issue** The claim of "maximum drug-like properties" is vague and not quantified. No specific ADMET parameters (e.g., Lipinski's rule of five, solubility, permeability) are reported.
- **Required correction** Specify which drug-likeness criteria were evaluated and report the relevant values for each compound.

## Risk / unsupported claims
- The claim that the compounds are "potential candidate[s] for patients with breast cancer" is unsupported without experimental validation.
- The claim of "maximum drug-like properties" is unquantified and cannot be assessed from the abstract.
- The epidemiological statistics in the opening are uncited and may be inaccurate.
- The binding affinity values are presented as absolute measures without acknowledgment of the limitations of docking-based predictions.
- The stability of the compounds over 200 ns simulations is asserted without supporting data or defined criteria.